Breakdown of the frequency of mutations as assessed by SS vs NGS by level of nonresponse and line of therapy
| . | Patients positive for mutations by SS . | Patients positive for mutations by NGS . |
|---|---|---|
| First-line failure | 13/57 (23) | 27/57 (47) |
| First-line warning | 7/68 (10) | 23/68 (34) |
| Second-line failure | 15/39 (38) | 20/39 (51) |
| Second-line warning | 6/37 (18) | 17/37 (49) |
| Third-line failure | 14/21 (67) | 17/21 (80) |
| Third-line warning | 1/7 | 3/7 |
| Fourth-/fifth-line failure | 4/7 | 4/7 |
| Total | 60/236 (25) | 111/236 (47) |
| . | Patients positive for mutations by SS . | Patients positive for mutations by NGS . |
|---|---|---|
| First-line failure | 13/57 (23) | 27/57 (47) |
| First-line warning | 7/68 (10) | 23/68 (34) |
| Second-line failure | 15/39 (38) | 20/39 (51) |
| Second-line warning | 6/37 (18) | 17/37 (49) |
| Third-line failure | 14/21 (67) | 17/21 (80) |
| Third-line warning | 1/7 | 3/7 |
| Fourth-/fifth-line failure | 4/7 | 4/7 |
| Total | 60/236 (25) | 111/236 (47) |
Definitions for second-line failure and warning were also applied to third-, fourth-, and fifth-line patients. Data are presented as n (%) of patients.